FDA
-
-
-
-
-
-
-
Citius Oncology secures $36.5 million in debt and equity financing
-
-
-
-
-
-
-
Citius Oncology reports early commercial progress for LYMPHIR drug launch
-
-
-
-
-
-
-
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
-
-
-
-
-
-
-
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
-
-
-
-
-
-
-
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
-
-
-
-
-
-
-
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIRâ„¢
-
323,729 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

